GRA_Logo

 + Home + About Us + Contact Us
 
+ Drug Delivery  + Monitoring   + Drug Therapeutics   + Medical Devices  + Pain & CNS   + Tissue
 
Closed Drug Transfer Systems
Therapeutic Markets, Strategies and Outlook


About This Report

Price: US $2,850

Publication: January 2013

Product Code: CDT884R





Drug Delivery Reports

Prefilled Syringes to 2016
Pen Injectors
Sustained Release Injectables
Injectable Drug Delivery 2016
Cartridge-based Injectors
Integrated Safety Syringes
Drug Reconstitution Systems
Autoinjectors to 2016
Dual Chamber Injectors
Needle-free Injectors
IV Fluid Transfer Devices
Smart Infusion Pumps
Inhaled Drug Delivery to 2016
Dry Powder Inhalation
Inhaled CNS Therapeutics
Pulmonary Inhalers
Inhaled Pain Management
Prescription Drug Patches
Microneedle Drug Delivery
Patch Pump Drug Delivery
Transdermal CNS Therapeutic
Needle Array Drug Delivery
Transdermal Pain Mgmt
Oral Transmucosal Delivery
Iontophoresis Drug Delivery
Therapeutic Proteins to 2016
Pediatric Drug Delivery
Closed Drug Transfer System
Drug Self-Administration 2016
Drug Solubiity
 
 
 
 
 
 
 
 
 
 
The administration of drugs deemed hazardous to humans has been receiving increasing amounts of scrutiny in recent years as the dangers of these substances become more clearly understood. For caregivers and their patients, the therapeutic area that is at the forefront of attempts to mitigate exposure to cytotoxic drugs is clinical oncology, a field that – in spite of promising new drugs based on therapeutic antibodies – continues to rely heavily on antineoplastics, a class that includes alkylating agents and antimetabolites, to treat a wide range of cancers. Regulatory and industry efforts to create standards and procedures designed to protect workers and patients from accidental and incidental exposure to cytotoxics are being driven by data that suggests a causal link between exposure and health issues. Studies of nurses who work with cytotoxic drugs on a regular basis have found a statistically higher rate of spontaneous abortion. Several companies are responding to this unmet need by commercializing devices for closed transfer of these drugs. As the market evolves and user acceptance increases, so too will the impact of these products on oncology therapy protocols and drug delivery
Highlights

· Analyzes the impact of drug toxicity and safety factors on therapeutic oncology market segments, market dynamics and market demographics

· Provides detailed analysis of closed drug transfer products for the handing of cytotoxic drugs

· Analyzes demand drivers and competitive factors influencing closed drug transfer adoption

· Charts product data and provides forecasts to 2017

· Profiles closed drug transfer device participants, their product development activities, business strategies, and corporate alliances and affiliations
Summary of Contents
Executive Summary

Oncology Therapeutics Market Dynamics

Therapeutic Trends and Issues
The Administration of injectable/Infusable Antineoplastics
Drug Packaging and Administration Technology
Closed Drug Transfer Market Drivers
Competitive Landscape
Risk Factors

Closed Drug Transfer Design Factors

Key System Design Elements
Human Engineering/Ergonomics
Material Selection Issues
Drug Reconstitution and Dilution
Oncology Therapeutics Medication Safety
Oncology Drug Administration and Dosing
Drug-Specific Dosing Modification and Individualized Dosing

Closed Drug Transfer – Commercial Device Assessments and Market Data

Market Factors

Regulatory Issues
Caregiver Compliance
Level of Complexity and Ease of Use
Healthcare Economics
Business Models and Strategies

Market Assessments and Forecasts

North America
Europe
Asia
Other Geographic Markets

Closed Drug Transfer – Market Participant Profiles




 

 

Recent Research

Prefilled Syringes to 2018

Pen Injectors

Drug Self-Administration

Injectable Drug Delivery to 2018

Autoinjectors to 2018


Events

Drug Delivery & Formulation Summit - San Diego (April 2013)

Partnerships in Drug Delivery  - Boston (October 2013)

 
     
 
Greystone Research Associates
98 Route 101A, Suite 17
Amherst, NH 03031 USA

Phone: 603-595-4340/ Fax: 603-218-7020
Copyright 2013 ·  Greystone Research Associates  ·  All Rights Reserved · Conditions of Use  ·  Career